In the present study, we examined the effectiveness of shallomin, the active antimicrobial constituent of Persian shallot, in treatment of patients who developed cold sore within the previous 24 hours. The results showed that 0.5% shallomin led to a rapid clearance of the sores after five to six hours following hourly topical application with no significant side effects and with a minimal crust or scab formation.
Previous studies have shown that different modalities of treatment ranging from ice, licorice, topical anesthetics agents, analgesics, and even milk can reduce the duration of cold sore. Zinc lozenges can also be used as they boost the immune systems. The current and widely used treatment of severe recurrent cold sore is oral or topical acyclovir. This drug is also used to treat genital herpes and herpes zoster. This agent is a guanosine analogue, which specifically inhibits herpes virus DNA polymerase. Acyclovir therapy neither eliminates latent virus nor prevents subsequent recurrences (
12).
It is well known that cold sores manifest differently in duration and severity even in an individual. In this study, in order to reduce this confounding factor, we recruited cases that had similar profiles of recurrence and severity. This was achieved by preliminary completion of demographic characteristics and the history of their previous cold sores in terms of duration and severity, and cases that had recurrences with at least three-month intervals and sores durations ranging from seven to ten days were recruited.
Previous studies have shown that although acyclovir reduces the duration of healing and the intensity of pain associated with herpes labialis, it does not affect the progression stage of crust formation. This benefit was more significant when the patients started a five times a day oral treatment during the prodromal or erythematous stages than when initiated during papular or late macular stages. The mean duration was reduced from 7.9 to 5.8 days
13). However, regardless of the time of initiating treatment, no differences in the benefits between five times a day and topical application of 5% acyclovir were seen. The mean healing time were 4.3 and 4.8 days for medication and placebo, respectively (
14). The results from the present study showed that the alcoholic solution of 0.5% shallomin produced a rapid clearance of cold sore in 30% of cases within six hours and all the sores were cleared within 24 hours when applied during the early stages. The selected concentration was made from our dose-finding pilot study. Further studies should be conducted to assess its effectiveness when applied during the late stages; however, these findings suggest that shallomin is a more potent antiviral agent that acyclovir.
In a recent study, a preliminary
in vivo toxicological evaluation of escalating doses of shallomin was performed and demonstrated that shallomin was a relatively safe drug when administrated at its standard expected antimicrobial concentration by intraperitoneal route (
8). This finding suggests that shallomin can be administered systemically for treatment of more severe forms of herpes infections. A preliminary, unpublished, clinical study by our group showed that shallomin is also effective in the treatment of HSV-2, a more common cause of genital herpes.
With regard to the clinical implication of these findings, herpes infections have been implicated as the causative agent in various diseases in different body systems such as neonatal herpes simplex, a rare but serious infection that is transmitted vertically from mother to newborn. It also produces unusual lesions on the skin during immunodeficiency such as herpes syncosis, a recurrent infection primarily affecting the hair follicles. Moreover, eczema herpeticum is a spreading form of herpes in the areas inflicted with chronic eczema.
The cumulative results from this study and those reported from other previous studies demonstrated that shallomin, at different concentrations, is a relatively safe and a potent chemotherapeutic agent of natural origin, having a wide range of activity against bacteria, fungi, and viruses, a quality that has not been reported previously for any of the known chemotherapeutic agents (
6,
7,
9). Considering the safety profile of this agent, employment of this agent in conditions where HSV is implicated as the causative agent can be assessed in future studies and this agent may find its wider use in clinical settings. In conclusion, the findings from our study demonstrated that shallomin is a useful and effective treatment modality with more rapid response. Its usage is recommended in treatment of cold sores when applied within 24 hours of development.